Abstract
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are closely related progressive disorders with no available causal therapy, neuropathologically characterized by intraneuronal aggregates of misfolded α-synuclein. To explore the role of DNA methylation changes in PD and DLB pathogenesis, we performed an epigenome-wide association study (EWAS) of 322 postmortem frontal cortex samples and replicated results in an independent set of 219 donors. We report novel differentially methylated replicating loci associated with Braak Lewy body stage near SFMBT2, PHYHIP, BRF1/PACS2 and DGKG. The DGKG locus also showed evidence of DNA methylation changes in the earliest, preclinical stage of disease. Differentially methylated probes were independent of known PD genetic risk alleles. Meta-analysis provided suggestive evidence for a differentially methylated locus within the chromosomal region affected by the PD-associated 22q11.2 deletion. Our findings elucidate novel disease pathways in PD and DLB and generate hypotheses for future molecular studies of Lewy body pathology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the Norwegian Health Association (grant 4799) and the Research Council of Norway. L.P. and M.T: also received additional funding from the South-Eastern Regional Health Authority, Norway, the Norwegian Parkinson Research Fund and Reberg's Legacy. WB received funding from the Dutch Parkinson association, Health Holland and Rotary Club Aalsmeer-Uithoorn. The Brains for Dementia Research cohort, including the generation of DNA methylation data, is jointly funded by the UK Alzheimer's Society and Alzheimer's Research UK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical Ethics Committee of the VU University Medical Centre, Amsterdam, approved all procedures of NBB and NABCA. BDR is approved as a Research Tissue Bank by the UK National Research Ethics Service. The study was approved by the South-East Regional Committee for Health and Medical Research Ethics, Norway, (Committee South-East A, 30552).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Following peer-reviewed publication, genotype and methylation data for the Netherlands Brain Bank cohort will be made publicly available through the Netherlands Neurogenetics Database (https://www.brainbank.nl/nnd-project/). Data from the Brains for Dementia Research cohort are available through application to the Medical Research Council UK Brain Banks Network (https://mrc.ukri.org/brain-banks/) and Dementias Platform UK (https://portal.dementiasplatform.uk).
https://www.brainbank.nl/nnd-project/
